|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Abnormalities in ATM and TP53 genes represent important predictive factors in chronic lymphocytic leukemia (CLL); however, the efficacy of CD20 targeting immunotherapy is only poorly defined in the affected patients.
|
24970561 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Combined imaging/ fluorescence-in-situ hybridization performed in four SM-AHNMD cases revealed shared abnormal signals in mast cells and myeloid cells in two patients with SM-CMML and one patient with SM-MDS, but not in the mast cells of a case SM-associated with chronic lymphocytic leukemia with ATM-deletion.
|
23440662 |
2013 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Detection of a 17p13.1 deletion (loss of TP53) or 11q22.3 deletion (loss of ATM), by fluorescence in situ hybridization (FISH), in chronic lymphocytic leukaemia (CLL) patients is associated with a poorer prognosis.
|
24032430 |
2013 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia.
|
23614766 |
2013 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, ATM mutations either alone or in combination with 11q deletion uniformly led to demonstrable ATM dysfunction in patients with chronic lymphocytic leukemia and mutation presence can be predicted by the functional test using doxorubicin.
|
23585524 |
2013 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
This study sought to establish whether functional analysis of the ATM-p53-p21 pathway adds to the information provided by currently available prognostic factors in patients with chronic lymphocytic leukemia (CLL) requiring frontline chemotherapy.
|
22675167 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
The purpose of dynamic assessment of p53 response in CLL is to carry out a comprehensive analysis of all mechanisms causing p53-deficient phenotype, including those unrelated to genomic aberrations of TP53 and ATM.
|
22280536 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
The most common cytogenetic abnormalities with independent prognostic significance in CLL are 13q14, ATM and TP53 deletions and trisomy 12.
|
22228453 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A new minimal deleted region at 11q22.3 reveals the importance of interpretation of diminished FISH signals and the choice of probe for ATM deletion screening in chronic lymphocytic leukemia.
|
21955805 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
To better define the significance of clonal evolution (CE) including 14q32 translocations involving the immunoglobulin heavy chain gene (IGH) in chronic lymphocytic leukemia (CLL), 105 patients were analyzed sequentially by fluorescence in situ hybridization (FISH) with the following panel of probes: 13q14/D13S25, 11q22/ATM, 17p13/TP53, #12-centromere and 14q32/IGH break-apart probe.
|
21767243 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
|
23091097 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Overall, ATM point mutations and deletions were detected in 14/57 (24.6%) cases at presentation, representing the most common unfavorable genetic anomalies in chronic lymphocytic leukemia, also in stage A patients.
|
21993670 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
These data in aggregate demonstrate a low frequency of ATM aberrations in an unselected CLL cohort and do not support a major prognostic role for ATM aberrations in CLL, thus motivating renewed research efforts aimed at understanding the pathobiology of 11q deletions in CLL.
|
22952040 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our data indicate that truncating ATM mutations are rare in patients with CLL.
|
22369572 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Drug resistance in chronic lymphocytic leukemia (CLL) associated with lesions in the ATM/TP53 pathway represents a major challenge in clinical management.
|
22149137 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
These results suggest that ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but rather influences rapid disease progression through ATM loss.
|
21933854 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data provide the first evidence for the existence of a putative "hepitype" in the ATM gene associated with CLL risk.
|
21910157 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Recurrent losses or gains of genomic material as well as mutations of key tumor suppressors (ATM and TP53) have been identified in chronic lymphocytic leukemia (CLL).
|
21435757 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
The DNA damage pathway plays a central role in chemoresistance in chronic lymphocytic leukemia (CLL), as indicated by the prognostic impact of TP53 and ATM loss/mutations.
|
21115975 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Nine genes that are mutated at significant frequencies were identified, including four with established roles in chronic lymphocytic leukemia (TP53 in 15% of patients, ATM in 9%, MYD88 in 10%, and NOTCH1 in 4%) and five with unestablished roles (SF3B1, ZMYM3, MAPK1, FBXW7, and DDX3X).
|
22150006 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Array comparative genomic hybridization testing was performed on 55 cases of CLL in addition to a standard panel of FISH probes (ATM on 11q22, trisomy 12, 13q14, p53 on 17p13).
|
21143592 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
We have obtained quantitative measurements of radiation-induced apoptosis and radiation-induced ATM autophosphorylation in purified CLL cells from 158 and 140 patients, respectively, and have used multivariate analysis to identify independent contributions of various biological variables on genomic complexity in CLL.
|
20086003 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
We investigated in vitro sensitivity to the poly (ADP-ribose) polymerase inhibitor olaparib (AZD2281) of 5 ATM mutant lymphoblastoid cell lines (LCL), an ATM mutant MCL cell line, an ATM knockdown PGA CLL cell line, and 9 ATM-deficient primary CLLs induced to cycle and observed differential killing compared with ATM wildtype counterparts.
|
20739657 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Nonetheless, non-mutated IgV(H) gene rearrangement, ATM (11q22-23) and p53 (17p13) deletion are recognized as unfavorable prognosticators in chronic lymphocytic leukemia.
|
19898425 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Inhibitors of heat-shockprotein 90 (Hsp90) have been proposed as a novel therapeutic option for Chronic Lymphocytic Leukaemia (CLL), particularly as their mechanism of action appears independent of mutations of ATM or TP53.
|
20738310 |
2010 |